Welcome from our chairperson

Welcome to HaemOnc 2026.

The South African Clinical Haematology Society is proud to welcome you to HaemOnc 2026, taking place in Cape Town under the theme “Beyond Boundaries: From Progress to Access.”

This year’s meeting focuses on a defining challenge in haematology and oncology: moving beyond discovery to ensure that innovation reaches patients in meaningful and sustainable ways. While scientific progress continues to accelerate, access to diagnostics and treatment remains a pressing issue across many healthcare systems.

HaemOnc 2026 will bring together clinicians, laboratory specialists, researchers, industry partners, and policymakers to explore practical pathways from innovation to implementation. Through integrated clinical and diagnostic perspectives, local and international expertise, and robust academic engagement, the meeting aims to drive collaboration and real-world solutions.

We look forward to welcoming you to a meeting that is purposeful, forward-thinking, and firmly focused on improving patient care.

Vernon Louw
President: South African Clinical Haematology Society (SACHaS)

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

b

Registration

Early bird: 01 Mar – 30 Jun 2026
Late: 01 Jul  – 05 Sep 2026

l

Abstracts

Opening date: 01 Mar 2026
Closing date: 24 August 2026

Trade

Join us to contribute to and take part in another memorable HaemOnc experience.

Adcock Ingram, a Proudly South African company was founded over 130 years ago in 1891. The Company has an extensive portfolio, including well-known household brands. Adcock Ingram manufactures, markets, sells and distributes a wide range of products. The diversified portfolio includes non-price-regulated healthcare, consumer products, a strong presence in over the counter, an extensive portfolio of branded and generic prescription medicines. As the largest supplier to the private sector in South Africa, the Company provides work to more than 2 000 employees. Bidvest Group Limited has a majority ownership with Natco Pharma, an Indian-based pharmaceutical Company, as the other shareholder. Our mission is to provide quality products that improve the health and lives of the people in the markets that we serve.

Hematology is a complex and challenging area of medicine. At Roche, finding innovative solutions for those affected by diseases of the blood is not only a priority, it's in our blood. Our commitment extends beyond developing innovative therapies, to playing a wider role in improving patient's quality of life. We are exploring the best ways to deliver innovations to patients as quickly and effectively as possible, which includes evolving and improving how our clinical trials are designed and how our therapies are administered. We are also looking at new ways to measure treatment success through the use of alternative clinical endpoints.

We continue to invest in bringing innovative treatment options to people with diseases of the blood, as our teams strive to continually deliver transformational change for patients and the physicians who treat them.

https://www.roche.com/solutions/focus-areas/haematoloqy

Roche Products (Pty) Ltd. Reg. No. 1947/027044/07. Building E, Hertford Office Park, 90 Bekker Road, Vorna Valley, Midrand, 1686. P.O. Box
1469, Halfway House, 1685. +27 (0)11 504 4746 or Toll-free on REAL (Roche Ethical Assistance Line): +27 (0)800 21 21 25
M-ZA-00003254 | Expiry Date: August 2028

Aspen is a global specialty and branded pharmaceutical company. With more than 170 years of heritage. Aligned with our ethos “Healthcare. We Care.”, our basket reflects a combination of legacy, innovation, and reliability, positioning Aspen as a preferred and trusted partner in advancing healthcare. We are dedicated to enhancing patient health and quality of life.

BeOne Medicines is a global oncology company dedicated to transforming cancer care through scientific excellence, innovation, and exceptional speed. Our fully integrated model spans discovery, development, manufacturing, and commercialization, enabling us to bring breakthrough therapies to patients faster. With one of the world's largest oncology-focused R&D organizations and a pipeline of more than 45 clinical and commercial-stage assets, we are advancing the future of cancer treatment. Through a commitment to expanding access worldwide, BeOne is working to reach more patients than ever before. Together, we are how the world stops cancer.

To find out more, please visit: www.beonemedicines.co.za

BeOne Medicines South Africa (Pty) Ltd. VilleBois Office Park, Building 2 - 920 De Ville Bois Mareuil Drive, Moreleta Park, X36,Pretoria, Gauteng, 0044, South Africa. Reg. No:1996 / 011587 / 07. Tel: 076 509 0279. Toll-free number: 0800 983 530.

Contact details: For general information: infosa@beonemed.com. Adverse events: patientsafetyza@beonemed.com

BEI-066-0926

Agios is a commercial-stage biopharmaceutical company. The company’s vision is to redefine the future of rare disease treatment. With a foundation in hematology, Agios combines biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people it serves. Visit www.agios.com.
 

About AstraZeneca

AstraZeneca is a science-led, patient-focused biopharmaceutical company committed to transforming healthcare and improving outcomes. We believe science, powered by digital, data and AI, is key to addressing the world’s most pressing healthcare challenges.

We strive to improve access to life-changing medicines and pioneering solutions, while also supporting earlier detection, integrated care pathways, and stronger health systems so more people can receive the right care at the right time. Powered by scientific innovation, and increasingly enabled by digital, data and AI, we are helping redefine cancer care, improve outcomes in chronic diseases, and expand access to care in a sustainable and responsible way.

Activity ID: ZA-6886; Expiry date: 30 June 2028

https://www.astrazeneca.com/country-sites/african-cluster.html

About Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built on our heritage in diabetes. Through scientific innovation, expanded access to medicines, and partnerships across healthcare and technology, we help bring meaningful solutions to patients worldwide. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 304 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter, Instagram and YouTube.

Loading...